Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized …

Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets
soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble …

Anxiety and stress disorders are the most commonly occurring of all mental illnesses, and
current treatments are less than satisfactory. So, the discovery of novel approaches to treat …

Basal extracellular glutamate sampled in vivo is present in micromolar concentrations in the
extracellular space outside the synaptic cleft, and neither the origin nor the function of this …

Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated
Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and …

The nucleus accumbens in a brain region considered to be important in the regulation of
appetitive behavior and reinforcement. The accumbens receives afferent input from …

Members of the APOBEC (apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1-like)
family of cytidine deaminases inhibit host cell genome invasion by exogenous …

Increased glutamate transmission in the nucleus accumbens and ventral tegmental area has
been proposed as a mechanism underlying sensitized behavioral responses to repeated …

Background Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD)
have been in development over the last decade. BAN2401 is a monoclonal antibody that …

Atomoxetine is a selective inhibitor of norepinephrine transporters and is currently being
used in the pharmacotherapy of attention deficit/hyperactivity disorder (ADHD). We have …